Notification of major interest in shares

RNS Number : 7547C

Hikma Pharmaceuticals Plc

21 January 2015

 



Notification of major interests in shares

LONDON, 21 January 2015 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX: HIK), the fast growing multinational pharmaceuticals group, announces as follows:

1

Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached

Hikma Pharmaceuticals PLC

2	Reason for the notification
	An acquisition or disposal of voting rights	Yes
	An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached	No
	An event changing the breakdown of voting rights	No
	Other (please specify): Compliance with the Transparency Directive	No

3	Full name of the person subject to the notification obligation						FMR LLC
4	Full name of shareholders						See attached schedule
5	Date of the Transaction (and date on which the threshold crossed is reached differently)						19 January 2015
6	Date on which the issuer notified						20 January 2015
7	Threshold that is crossed						5%
8	Notified details						See A, B & C below
A. Voting rights attached to shares
Class type of shares (if possible using the ISIN code)		Situation previous to the triggering transaction		Resulting situation after the triggering transaction
		Number of shares	Number of voting rights	Number of shares		Number of voting rights			% of voting rights
				Direct	Indirect	Direct		Indirect	Direct	Indirect
Ordinary Shares (0.10 GBP) GB00B0LCW083		10,043,409	10,043,409	-	9,893,409	-		9,893,409	-	4.98

B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial instrument	Expiration Date	Exercise/Conversion Period/Date	Number of voting rights that may be acquired if the instrument if exercised/converted	% of voting rights
-	-	-	-	-

C: Financial Instruments with similar economic effect to Qualifying Financial Instruments
Resulting situation after the triggering transaction
Type of financial instrument	Exercise Price	Expiration Date	Exercise/Conversion Period/Date	Number of voting rights instrument refers to	% of voting rights
					Nominal	Delta
-	-	-	-	-	-	-

Total A+B+C
Number of Voting rights	% of voting rights
9,893,409	4.99%

9	Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable

Proxy Voting
10	Name of the proxy holder	Custodian Day to Day IM Total BANK OF NEW YORK BRUSSELS (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 8,051 BANK OF NEW YORK MELLON PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 156,712 BROWN BROTHERS HARRIMAN AND CO FMR UK-FIDELITY MANAGEMENT & RESEARCH (U.K.) INC. 25,001 PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 68,425 PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 822,664 CIBC MELLON TRUST (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 19,726 CITIBANK NA, HONG KONG BR (S) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 21,821 JP MORGAN, BOURNEMOUTH (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 13,981 PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 219,471 JPMORGAN CHASE BANK FMR UK-FIDELITY MANAGEMENT & RESEARCH (U.K.) INC. 162,476 FMRC-FMR CO., INC 3,337,724 PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 42,456 PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 83,696 MELLON BANK NA (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 388,798 NATIONAL BANK TRUST (C) PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 20,223 NOMURA TRUST AND BANKING (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 294 NORTHERN TRUST CO (C) FMR UK-FIDELITY MANAGEMENT & RESEARCH (U.K.) INC. 2,865,472 PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 371,824 STATE STREET BANK AND TR CO FMRC-FMR CO., INC 244,499 PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 453,252 PGATC-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 543,597 US BANK NA (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 23,246 Grand Total 9,893,409
11	Number of voting rights proxy holder will cease to hold	N/A
12	Date on which proxy holder will cease to hold voting rights	N/A

13	Additional Information
14	Contact name:	Peter Speirs, Company Secretary
15	Contact telephone number:	020 7399 2772

- ENDS -

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products.  Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe.  In 2013, Hikma achieved revenues of $1,365 million and profit attributable to shareholders of $212 million. 

 

END

 

 

HOLBBMBTMBBTBFA